News Release

Norfolk, VA, April 5, 2022 – ReAlta Life Sciences, Inc. announced today that Dr. Ulrich Thienel, MD, PhD, Chief Executive Officer is scheduled to participate in the upcoming 21st Annual Needham Virtual Healthcare Conference, from April 11-14, 2022. The virtual meeting brings public and private companies in the Biotechnology, Specialty Pharmaceutical, Medical Technology, and Diagnostic sectors together with institutional, private equity, and venture capital investors.

Dr. Thienel will meet with investors during the event to discuss the development of ReAlta’s dual-targeting peptide technology platform to deliver game-changing new therapies for hypoxic-ischemic encephalopathy (HIE) and other life-threatening rare diseases. The company recently received IND clearance for RLS-0071 to initiate its Phase 2 STAR trial in neonates with HIE.

About ReAlta Life Sciences

ReAlta Life Sciences, Inc. is a clinical-stage, rare disease biotech company dedicated to harnessing the power of the immune system to address life threatening diseases. The Company’s EPICC peptides are based on research into the human astrovirus HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has received IND approval, and Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018 and is located in Norfolk, Virginia.

For more information, please visit www.realtalifesciences.com.